Aug 12, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26
Denali Therapeutics posts narrower-than-expected Q2 loss. The company advances multiple rare disease therapies toward potential approvals.
Aug 05, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Catalyst Pharmaceutics to Report Q2 Earnings: What's in the Cards?
CPRX gears up to report Q2 results as Firdapse sales rise, Agamree grows, and Fycompa faces a post-patent dip.
Jul 30, 2025 • Zacks Commentary
NEUTRAL
Amgen Gears Up to Report Q2 Earnings: Will the Beat Streak Continue?
AMGN eyes another earnings beat as strong drug volumes offset pricing pressure and biosimilar headwinds.
Jul 23, 2025 • Benzinga
SOMEWHAT-BULLISH
Tenvie Therapeutics Promotes Tony Estrada, PhD, to Chief Executive Officer
SOUTH SAN FRANCISCO, Calif., July 23, 2025 ( GLOBE NEWSWIRE ) -- Tenvie Therapeutics, a biotechnology company committed to engineering small molecules that transform the treatment of neurological diseases, today announced the appointment of Tony Estrada, Ph.D., as President and Chief Executive ...
Jul 17, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors
NEW YORK, July 17, 2025 ( GLOBE NEWSWIRE ) -- Royalty Pharma plc ( Nasdaq: RPRX ) today announced the appointment of Carole Ho and Elizabeth ( Bess ) Weatherman to its Board of Directors, effective immediately. Carole Ho is Chief Medical Officer and Head of Development at Denali Therapeutics, a ...
Jul 17, 2025 • Benzinga
SOMEWHAT-BULLISH
Royalty Pharma Appoints Carole Ho and Elizabeth Weatherman to the Company's Board of Directors - Royalty Pharma ( NASDAQ:RPRX )
Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90% Underscores Royalty Pharma's commitment to enhanced corporate governance following acquisition of its external manager